Document is current
Any future updates will be listed below
-
Authors
Boughey, Judy C. https://orcid.org/0000-0003-3820-3228
Yu, Hongmei
Dugan, Catherine Lu
Piltin, Mara A.
Postlewait, Lauren
Son, Jennifer D.
Edmiston, Kirsten K.
Godellas, Constantine V.
Lee, Marie C.
Carr, Michael J.
Tonneson, Jennifer E.
Crown, Angelena
Lancaster, Rachel B.
Woriax, Hannah E.
Ewing, Cheryl A.
Chau, Harrison S.
Patterson, Anne K.
Wong, Jasmine M.
Alvarado, Michael D.
Yang, Rachel L.
Chan, Theresa W.
Sheade, Jori B.
Ahrendt, Gretchen M.
Larson, Kelsey E.
Switalla, Kayla
Tuttle, Todd M.
Tchou, Julia C.
Rao, Roshni
Tamirisa, Nina
Singh, Puneet
Gould, Rebekah E.
Terando, Alicia
Sauder, Candice
Hewitt, Kelly
Chiba, Akiko
Esserman, Laura J.
Mukhtar, Rita A.
-
Funding
Funding for this research was provided by:
National Institutes of Health's National Cancer Institute (P01 CA210961)
Quantum Leap Healthcare Collaborative
- License Information
-
More Information
Article History
Received: 22 March 2023
Accepted: 1 June 2023
First Online: 28 June 2023
Disclosures
: Dr. Esserman is an uncompensated board member of the Quantum Leap Healthcare Collaborative, which sponsors the I-SPY TRIAL. She also reports that she is on the Blue Cross Medical Advisory Panel, is paid for travel, and is given an honorarium for her time; she leads an investigator-initiated vaccine trial for high-risk ductal carcinoma in situ, which is funded by Merck through the University of California San Francisco. There are no conflicts related to this manuscript. Dr. Singh reports funding to the institution for the trial through trial sponsors, specifically Foundation for the National Institutes of Health and ACRI. Dr. Tchou is a consultant for BD.
